TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34611132

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 143
Study: 32087257

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 °C for 24 hours
Number of subjects: 349

Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33 °C for 48 hours
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: AKI stages 2 and 3
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: AKI (overall)
Number of subjects: 349
Study: 33278292

Group type: EXPERIMENTAL
Intervention: hfTENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: sham
Number of subjects: 40
Study: 33502276

Group type: EXPERIMENTAL
Intervention: Flipped Learning (FL) in 2017 for Medical topics
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Flipped Learning (FL) in 2018 for the entire course
Number of subjects: 404

Group type: COMPARATOR
Intervention: Traditional Lecture (TL) in 2016 for the entire course
Number of subjects: 404
Study: 32293522

Group type: EXPERIMENTAL
Intervention: Scaling and root-planing treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tooth-brushing (usual care)
Number of subjects: 40
Study: 35142559

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (12 weeks, 3 days/week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonaerobic exercise (control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (Aerobic and Control)
Number of subjects: 48
Study: 34140144

Group type: EXPERIMENTAL
Intervention: Conventional-dose SRT (64 Gy)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Dose-intensified SRT (70 Gy)
Number of subjects: 350
Study: 32783554

Group type: EXPERIMENTAL
Intervention: 2-mSv CT
Number of subjects: 3074

Group type: COMPARATOR
Intervention: Standard-Dose CT (SDCT)
Number of subjects: 3074
Study: 36066168

Group type: EXPERIMENTAL
Intervention: 500 IU/day cholecalciferol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1000 IU/day cholecalciferol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison between 500 IU/day and 1000 IU/day cholecalciferol
Number of subjects: 60
Study: 32890573

Group type: EXPERIMENTAL
Intervention: SNP rs56151658 (test allele A)
Number of subjects: 34167

Group type: EXPERIMENTAL
Intervention: Multiple SNPs in strong linkage disequilibrium with rs56151658
Number of subjects: 34167

Group type: EXPERIMENTAL
Intervention: HLA genes (HLA-DQA2, HLA-DRB6, HLA-DOB)
Number of subjects: 34167
Study: 34404610

Group type: EXPERIMENTAL
Intervention: Electronic screening and feedback tool
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study: 33909361

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with psychological intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine psychological intervention (Control)
Number of subjects: 100
Study: 35363318

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice daily (n = 165)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Best available therapy (BAT) (n = 164)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 329

Group type: COMPARATOR
Intervention: BAT
Number of subjects: 329
Study: 33992241

Group type: EXPERIMENTAL
Intervention: Low-load-high-repetitions (LLHR) program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pilates program
Number of subjects: 42
Study: 35951014

Group type: EXPERIMENTAL
Intervention: 0.5% EGCG (10 mg/kg daily dose)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 33975579

Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT
Number of subjects: 300

Group type: COMPARATOR
Intervention: CT-guided SBRT
Number of subjects: 300
Study: 35233908

Group type: EXPERIMENTAL
Intervention: ertugliflozin 5 mg
Number of subjects: 8246

Group type: EXPERIMENTAL
Intervention: ertugliflozin 15 mg
Number of subjects: 8246

Group type: EXPERIMENTAL
Intervention: ertugliflozin (pooled)
Number of subjects: 8246

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8246
Study: 33587397

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OXT) 24 IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33096684

Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 70
Study: 616863419

Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre (GS) treatment
Number of subjects: 51
Study: 36131291

Group type: EXPERIMENTAL
Intervention: Metformin (initiated at 500mg/day, titrated to a maximum of 2500mg over 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 32036242

Group type: EXPERIMENTAL
Intervention: 750 mg of CBD (Epidiolex® or Epidyolex®) twice daily for 4 weeks followed by 2 weeks of 750 mg b.i.d. CBD (Part 2, Arm 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched placebo (Part 2, Arm 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 750 mg of CBD (Epidiolex® or Epidyolex®)
Number of subjects: 30
Study: 35361136

Group type: EXPERIMENTAL
Intervention: Dementia-friendly hospital program
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 423
Study: 34260859

Group type: EXPERIMENTAL
Intervention: Carer support program developed with a community‐based participatory action research (PAR) approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (delivery of information sessions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (PAR and control)
Number of subjects: 100
Study: 32092502

Group type: EXPERIMENTAL
Intervention: Elastic band resistance training (EBRT) for 12 weeks, 3 times per week, progressively increasing resistance from yellow to red to black Thera-Band.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group received telephone contacts or face-to-face interviews weekly to maintain typical diet and activity habits.
Number of subjects: 63
Study: 36336841

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg every 3 weeks)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 290
Study: 32988717

Group type: EXPERIMENTAL
Intervention: Field-in-field (FiF) technique
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Volumetric arc radiation therapy (VMAT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inverse intensity-modulated radiation therapy (IMRT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Helicoidal therapy
Number of subjects: 35
Study: 33547945

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (SCRT) followed by three cycles of consolidation chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX6)
Number of subjects: 19
Study: 32493494

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200mg once daily for two months (HC group)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 450
Study: 34723164

Group type: EXPERIMENTAL
Intervention: Nafamostat plus standard-of-care (SOC)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Nafamostat plus SOC
Number of subjects: 104

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Nafamostat
Number of subjects: 104
Study: 33066756

Group type: EXPERIMENTAL
Intervention: Physical exercise program
Number of subjects: 495
Study: 34978932

Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program (CHAMP)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control/Outdoor Free Play
Number of subjects: 99
Study: 32703205

Group type: EXPERIMENTAL
Intervention: Decision support tools including decision aids, consultation cards, decision cards, and practical training for vascular surgeons.
Number of subjects: 502
Study: 35021599

Group type: EXPERIMENTAL
Intervention: ibrutinib plus obinutuzumab
Number of subjects: 229

Group type: COMPARATOR
Intervention: chlorambucil plus obinutuzumab
Number of subjects: 229
Study: 34215316

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20 mg/day) with elemental calcium 1200 mg and vitamin D 800 IU daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (calcium 1200 mg and vitamin D 800 IU only)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bazedoxifene group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 34939373

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 34499319

Group type: EXPERIMENTAL
Intervention: Educational, expressional, and self-adjustment interventions
Number of subjects: 71

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 71
Study: 35733187

Group type: EXPERIMENTAL
Intervention: PBL-FC teaching method
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 75
Study: 34339747

Group type: EXPERIMENTAL
Intervention: Genetic predisposition toward telomere attrition (one Z score decrease in length)
Number of subjects: 41935

Group type: EXPERIMENTAL
Intervention: Polygenic score for telomere attrition
Number of subjects: 41935

Group type: EXPERIMENTAL
Intervention: Genetically predicted kidney function decrease
Number of subjects: 41935
Study: 32641163

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 800 mg orally in two doses followed by 400 mg daily in two doses and azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + placebo (HC group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + placebo (C-group)
Number of subjects: 0
Study: 36333903

Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 104

Group type: COMPARATOR
Intervention: Online-only instruction
Number of subjects: 104
Study: 33641208

Group type: EXPERIMENTAL
Intervention: Supragingival scaling
Number of subjects: 127

Group type: COMPARATOR
Intervention: Moderate to high RA disease activity
Number of subjects: 127

Group type: COMPARATOR
Intervention: Probing depth (PD)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Anti‐agalactosyl IgG titer
Number of subjects: 127
Study: 32423941

Group type: EXPERIMENTAL
Intervention: 6-module internet CBT programme
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 2500
Study: 36303439

Group type: EXPERIMENTAL
Intervention: Patients after lumbar fusion
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lumbosacral fixation group (patients)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with adjacent segments degeneration (ASD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 62
Study: 33724684

Group type: EXPERIMENTAL
Intervention: Decomposition method from economics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dimensional balancing methods such as propensity score matching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching regime model
Number of subjects: 0
Study: 32250503

Group type: EXPERIMENTAL
Intervention: ACE inhibitors/Angiotensin receptor blockers (ACEi/ARB)
Number of subjects: 56997

Group type: COMPARATOR
Intervention: Beta blockers (BB)
Number of subjects: 56997
Study: 36293938

Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 33879151

Group type: EXPERIMENTAL
Intervention: Unauthorized clinical trials for investigational products approved for marketing in Russia
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Unauthorized trials with mismatched therapeutic indications, posology, or administration method
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Unauthorized trial including a drug therapy intervention with an unapproved active substance
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Publications with advertisements for the medicinal product
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Claims of efficacy in publications with advertisements
Number of subjects: 26
Study: 33899214

Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg pre-operatively
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo pre-operatively
Number of subjects: 79
Study: 32458778

Group type: EXPERIMENTAL
Intervention: Recent antibiotic use
Number of subjects: 300

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oxacillin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 300
Study: 35678729

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with nearly all risk factors within target ranges
Number of subjects: 715143

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes with nearly optimal risk factor control
Number of subjects: 715143

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 715143

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 715143
Study: 32151878

Group type: EXPERIMENTAL
Intervention: NC Gut Relief Formula (5 g/d for 4 weeks, then 10 g/d for 4 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: NC Gut Relief Formula
Number of subjects: 43
Study: 34689170

Group type: EXPERIMENTAL
Intervention: FOLFIRI/bevacizumab
Number of subjects: 324

Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 324
Study: 34397196

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) foam, applied once daily for at least 4 weeks
Number of subjects: 164

Group type: COMPARATOR
Intervention: Vehicle foam, applied once daily for at least 4 weeks
Number of subjects: 164
Study: 32379535

Group type: EXPERIMENTAL
Intervention: Proximal retroflexion
Number of subjects: 692

Group type: COMPARATOR
Intervention: Second forward view
Number of subjects: 692
Study: 35666250

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) program, 10 sessions
Number of subjects: 226
Study: 32546726

Group type: EXPERIMENTAL
Intervention: CPX-351 at 50 units/m2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CPX-351 at 75 units/m2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CPX-351 at 100 units/m2
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (standard chemotherapy)
Number of subjects: 56
Study: 36288590

Group type: EXPERIMENTAL
Intervention: Repeated high‐voltage long‐duration PRF (group R)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard voltage PRF (group S)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High‐voltage long‐duration PRF (group H)
Number of subjects: 81
Study: 33827786

Group type: EXPERIMENTAL
Intervention: MyChildCMC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 35276778

Group type: EXPERIMENTAL
Intervention: Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD) - 500 mg bid of CBP and LFD for 30 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Low FODMAP diet (LFD)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD)
Number of subjects: 67
Study: 34060339

Group type: EXPERIMENTAL
Intervention: Penile traction therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study: 35064853

Group type: EXPERIMENTAL
Intervention: Adhesix™ mesh
Number of subjects: 270

Group type: COMPARATOR
Intervention: Progrip™ mesh
Number of subjects: 270
Study: 33403699

Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 0
Study: 34134877

Group type: EXPERIMENTAL
Intervention: Parent SMART + TAU
Number of subjects: 61

Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 61
Study: 32283854

Group type: EXPERIMENTAL
Intervention: Pilates program under hypoxic conditions (H trial)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pilates program under normoxic conditions (N trial)
Number of subjects: 10
Study: 35667569

Group type: EXPERIMENTAL
Intervention: Monthly pegcetacoplan treatment (AM)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Bimonthly pegcetacoplan treatment (AEOM)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Sham treatment (SM)
Number of subjects: 246
Study: 34449946

Group type: EXPERIMENTAL
Intervention: Vitrification treatment + 5?M of Retinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrification treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control fresh preantral follicles
Number of subjects: 0
Study: 36369901

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 48
Study: 34438218

Group type: EXPERIMENTAL
Intervention: Postural stability measures (MiniBEST test)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Postural sway area on a firm surface
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gaze stability measures (horizontal and vertical VOR gain)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gaze stability outcomes (DHI score)
Number of subjects: 41
Study: 32580977

Group type: EXPERIMENTAL
Intervention: Enhanced self-management (digital home monitoring with centralised specialist support)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Supported medical management (digital home monitoring alone)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Enhanced self-management
Number of subjects: 202
Study: 35851518

Group type: EXPERIMENTAL
Intervention: Single session of Botulinum toxin A injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Multiple sessions of multivitamins mesotherapy injection
Number of subjects: 24
Study: 33318152

Group type: EXPERIMENTAL
Intervention: Genetically predicted higher SHBG in men
Number of subjects: 179916

Group type: EXPERIMENTAL
Intervention: Genetically predicted higher SHBG in men (multivariable MR controlling for testosterone)
Number of subjects: 179916

Group type: COMPARATOR
Intervention: Genetically predicted higher SHBG in women
Number of subjects: 179916
Study: 36443174

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg then 25 mg x 5 doses)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (A1AT) (90 mg/kg x 6 doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 43
Study: 33819452

Group type: EXPERIMENTAL
Intervention: High-protein, high-calorie oral nutritional supplements (ONS), 2 bottles daily for 3 months
Number of subjects: 282
Study: 33210468

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control immunisations (PCV13 and DTaP-IPV-Hib) without 4CMenB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant regimen (4CMenB with control immunisations)
Number of subjects: 0
Study: 35920293

Group type: EXPERIMENTAL
Intervention: Wheat peptides (WP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 49
Study: 35643076

Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) supplementation: 2g intravenously during induction of anesthesia, 2g before aortic cross-clamp removal, and 1g every 8 hours for five postoperative days.
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no AA supplementation).
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) supplementation.
Number of subjects: 332
Study: 33685706

Group type: EXPERIMENTAL
Intervention: Sedated: lidocaine cornual nerve block, 0.5 mg/kg meloxicam (subcutaneously), and 0.2 mg/kg xylazine (intramuscularly)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nonsedated: lidocaine cornual nerve block and meloxicam
Number of subjects: 122
Study: 32800315

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 18

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 18
Study: 33184647

Group type: EXPERIMENTAL
Intervention: Biofortified (yellow) cassava
Number of subjects: 176

Group type: COMPARATOR
Intervention: White cassava (control)
Number of subjects: 176
Study: 32195639

Group type: EXPERIMENTAL
Intervention: 445-nm diode laser irradiation on metallic brackets for 15 seconds before debonding
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laser group (445-nm diode laser treatment)
Number of subjects: 70
Study: 34302745

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily orally)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study: 32791501

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 100
Study: 34362323

Group type: EXPERIMENTAL
Intervention: Certified online HIV report with exchange mechanism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Without exchange mechanism
Number of subjects: 0
Study: 36475325

Group type: EXPERIMENTAL
Intervention: Pubertal and menstrual health education intervention (seven 2-hour educational sessions)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 578
Study: 33571736

Group type: EXPERIMENTAL
Intervention: Palbociclib and cetuximab (arm A)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo and cetuximab (arm B)
Number of subjects: 125
Study: 32870276

Group type: EXPERIMENTAL
Intervention: Neutral wrist splint for 6 weeks (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neutral wrist splint for 12 weeks (group B)
Number of subjects: 30
Study: 35034653

Group type: EXPERIMENTAL
Intervention: Peripheral intermittent theta burst stimulation (piTBS) applied directly to spastic muscles, 8 sessions with supra threshold intensity
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study: 32414414

Group type: EXPERIMENTAL
Intervention: Jiao-tai-wan (JTW)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124